Connecting via Winsock to STN

Welcome to STN International!  Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | NOV 21 | CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present |
| NEWS 3 | NOV 26 | MARPAT enhanced with FSORT command |
| NEWS 4 | NOV 26 | CHEMSAFE now available on STN Easy |
| NEWS 5 | NOV 26 | Two new SET commands increase convenience of STN searching |
| NEWS 6 | DEC 01 | ChemPort single article sales feature unavailable |
| NEWS 7 | DEC 12 | GBFULL now offers single source for full-text coverage of complete UK patent families |
| NEWS 8 | DEC 17 | Fifty-one pharmaceutical ingredients added to PS |
| NEWS 9 | JAN 06 | The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo |
| NEWS 10 | JAN 07 | WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data |
| NEWS 11 | FEB 02 | Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE |
| NEWS 12 | FEB 02 | GENBANK enhanced with SET PLURALS and SET SPELLING |
| NEWS 13 | FEB 06 | Patent sequence location (PSL) data added to USGENE |
| NEWS 14 | FEB 10 | COMPENDEX reloaded and enhanced |
| NEWS 15 | FEB 11 | WTEXTILES reloaded and enhanced |
| NEWS 16 | FEB 19 | New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art |
| NEWS 17 | FEB 19 | Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01 |
| NEWS 18 | FEB 23 | Several formats for image display and print options discontinued in USPATFULL and USPAT2 |
| NEWS 19 | FEB 23 | MEDLINE now offers more precise author group fields and 2009 MeSH terms |
| NEWS 20 | FEB 23 | TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms |
| NEWS 21 | FEB 23 | Three million new patent records blast AEROSPACE into STN patent clusters |
| NEWS 22 | FEB 25 | USGENE enhanced with patent family and legal status display data from INPADOCDB |
| NEWS 23 | MAR 06 | INPADOCDB and INPAFAMDB enhanced with new display formats |
| NEWS 24 | MAR 11 | EPFULL backfile enhanced with additional full-text applications and grants |
| NEWS 25 | MAR 11 | ESBIOBASE reloaded and enhanced |
| NEWS 26 | MAR 20 | CAS databases on STN enhanced with new super role |

```
                  for nanomaterial substances
 NEWS 27  MAR 23  CA/CAplus enhanced with more than 250,000 patent
                  equivalents from China
 NEWS 28  MAR 30  IMSPATENTS reloaded and enhanced
 NEWS 29  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:14:09 ON 06 APR 2009

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 08:14:19 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 APR 2009  HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES:   5 APR 2009  HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10551737 R5 aryl R6 and R8 ring.str
```



chain nodes :
7 12 13 14 17 19
ring nodes :
1 2 3 4 5 6 8 10 11 20
chain bonds :
4-17 5-7 7-8 10-11 11-12 12-13 12-14 17-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-20 10-20
exact/norm bonds :
4-17 5-7 7-8 8-20 10-11 10-20 12-13 12-14 17-19
exact bonds :
11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S

G2:O,S

G3:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 17:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR




G1 C,O,S
G2 O,S
G3 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.48 | 0.70 |

FILE 'CAPLUS' ENTERED AT 08:14:35 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 08:14:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 41318 TO ITERATE

100.0% PROCESSED 41318 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

L3 0 L2

=> file marpat
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.50 187.58

FILE 'MARPAT' ENTERED AT 08:14:46 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 150 ISS 13 (20090403/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20090048322 19 FEB 2009
DE 102007039155 19 FEB 2009
EP 2022798 11 FEB 2009
JP 2009035500 19 FEB 2009
WO 2009024087 26 FEB 2009
GB 2451715 11 FEB 2009
FR 2920023 20 FEB 2009
RU 2346937 20 FEB 2009
CA 2618420 24 JAN 2009

The new MARPAT User Guide is now available at:
http://www.cas.org/support/stngen/stndoc/marpat.html.

=> s L1 SSS full
FULL SEARCH INITIATED 08:14:50 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 80459 TO ITERATE

51.3% PROCESSED 41260 ITERATIONS 35 ANSWERS

89.5% PROCESSED 72011 ITERATIONS 78 ANSWERS

97.1% PROCESSED 78164 ITERATIONS 91 ANSWERS

99.2% PROCESSED 79809 ITERATIONS ( 1 INCOMPLETE) 96 ANSWERS

```
 99.8% PROCESSED    80307 ITERATIONS  (     1 INCOMPLETE)       96 ANSWERS

100.0% PROCESSED    80459 ITERATIONS  (     2 INCOMPLETE)       97 ANSWERS
SEARCH TIME: 00.01.33

L4           97 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     131.94     319.52

FILE 'CAPLUS' ENTERED AT 08:16:34 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009  VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009  (20090405/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l4
L5           97 L4

=> s L5 AND PY<=2003
      24034941 PY<=2003
L6           39 L5 AND PY<=2003

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 39 ANSWERS - CONTINUE? Y/(N):y

L6   ANSWER 1 OF 39  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2003:892617  CAPLUS  Full-text
DOCUMENT NUMBER:          139:358786
TITLE:                    Treatment of diabetes and diabetic complications with
                          sodium-hydrogen exchanger type 1 (NHE-1) inhibitors
INVENTOR(S):              Tracey, Wayne Ross; Treadway, Judith Lee
PATENT ASSIGNEE(S):       Pfizer Products Inc., USA
SOURCE:                   PCT Int. Appl., 73 pp.
                          CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003092694 | A1 | 20031113 | WO 2003-IB1639 | 20030422 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2483927 | A1 | 20031113 | CA 2003-2483927 | 20030422 <-- |
| AU 2003219421 | A1 | 20031117 | AU 2003-219421 | 20030422 <-- |
| EP 1499317 | A1 | 20050126 | EP 2003-715232 | 20030422 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003009707 | A | 20050209 | BR 2003-9707 | 20030422 |
| MX 2004008646 | A | 20041206 | MX 2004-8646 | 20040906 |
| PRIORITY APPLN. INFO.: | | | US 2002-380028P P | 20020502 |
| | | | WO 2003-IB1639 W | 20030422 |

OTHER SOURCE(S): MARPAT 139:358786

AB The invention provides methods for treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia-reperfusion injury, diabetic cardiac ischemia-reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. The invention also provides combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, the combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia-reperfusion injury, diabetic cardiac ischemia-reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:892447 CAPLUS Full-text
DOCUMENT NUMBER: 139:358784
TITLE: Treatment of diabetes and diabetic complications with NHE-1 inhibitors
INVENTOR(S): Tracey, W. Ross; Treadway, Judith L.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030212104 | A1 | 20031113 | US 2003-428521 | 20030501 <-- |

PRIORITY APPLN. INFO.: US 2002-380028P P 20020502
OTHER SOURCE(S): MARPAT 139:358784
AB This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.

L6 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:796371 CAPLUS Full-text
DOCUMENT NUMBER: 139:307685
TITLE: Preparation of sulfonyl aryl or heteroaryl hydroxamic acid compounds as matrix metalloprotease inhibitors
INVENTOR(S): Bedell, Louis J.; Mcdonald, Joseph J.; Barta, Thomas E.; Becker, Daniel P.; Rao, Shashidhar N.; Freskos, John N.; Mischke, Brent V.; Getman, Daniel P.; Decrescenzo, Gary A.; Villamil, Clara I.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S. Pat. Appl. Publ., 200 pp., Cont.-in-part of U.S. Ser. No. 230,209.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030191317 | A1 | 20031009 | US 2000-728408 | 20001201 <-- |
| US 6794511 | B2 | 20040921 | | |
| WO 9838859 | A1 | 19980911 | WO 1998-US4300 | 19980304 <-- |
| W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 20010020021 | A1 | 20010906 | US 1999-230209 | 19990624 <-- |
| US 6380258 | B2 | 20020430 | | |
| US 20030073845 | A1 | 20030417 | US 2001-909227 | 20010719 <-- |
| US 6696449 | B2 | 20040224 | | |
| US 20050075374 | A1 | 20050407 | US 2004-867391 | 20040614 |

PRIORITY APPLN. INFO.:
WO 1998-US4300 A1 19980304
US 1999-310813 B1 19990512
US 1999-230209 A2 19990624
US 1997-35182P P 19970304
US 2000-569034 A2 20000511
US 2000-728408 A2 20001201

OTHER SOURCE(S): MARPAT 139:307685
GI



I

AB The title compds. [I; m, n = 0 or 1 and the sum of m + n is 0 or 1; the ring structure W is a 5- or 6-membered aromatic or heteroarom. ring; X = CH2 or (un)substituted NH2; R1 = (i) a substituent containing a 5- or 6-membered cyclohydrocarbyl, heterocyclyl, aryl or heteroaryl radical bonded directly to the depicted SO2 group or (ii) (un)substituted; R2, R3 = H, alkyl, alkenyl, alkynyl, hydroxyalkyl, O- or S-(un)substituted hydroxyalkyl or mercaptoalkyl, hydroxy, thiol, haloalkyl, N-(un)substituted amino, aminoalkyl, aminoalkanoylaminoalkyl, aminoalkoxy, or aminoalkoxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylthio, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylthio; or CR2R3 together forms an (un)substituted 4- to 8-membered carbocyclic or heterocyclic ring, that is preferably a 5- or 6-membered ring; R5, R6 = H, alkyl, cycloalkyl, acylalkyl, halo, NO2, HO, cyano, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, N-(un)substituted aminoalkyl or aminoalkoxy, thiol, alkylthio, arylthio, cycloalkylthio, cycloalkoxy, alkoxyalkoxy, perfluoroalkyl, haloalkyl, heterocyclyloxy; or R5 and R6 together with the atoms to which they are bonded form a further aliphatic or aromatic carbocyclic or heterocyclic ring having 5- to 7-members; R20 = each (un)substituted OH, NHOH, or NH2] or pharmaceutically acceptable salts thereof are prepared Also disclosed is a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroarom. ring hydroxamic acid compound in a matrix metalloprotease (MMP) enzyme-inhibiting effective amount to a host having a condition associated with pathol. MMP activity. Thus, thioetherification of 4-phenoxybenzenethiol with 2-fluorobenzaldehyde in the presence of K2CO3 in isopropanol under reflux for 20 h gave 2-(4-phenoxyphenylthio)benzaldehyde which was condensed with tetra-Et dimethylaminomethylenediphosphonate in the presence of NaH in THF at room temperature for 4 h gave to 2-[2-(4-phenoxyphenylthio)phenyl]acetic acid (II). II was oxidized by H2O2 in acetic acid to 2-[2-(4-phenoxyphenylsulfonyl)phenyl]acetic acid which was condensed with O-tetrahydropyranylhydroxylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in MeCN followed by treatment with p-toluenesulfonic acid in methanol at room temperature for 2 h to give N-hydroxy-2-[2-(4- phenoxyphenylsulfonyl)phenyl]acetamide (III). III and N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide showed IC50 of >10,000 nM against MMP-1, 0.3 and 2.4 nM, resp., against MMP-2, and 2 and 2.7 nM, resp., against MMP-13.

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:591152 CAPLUS Full-text

DOCUMENT NUMBER: 139:149539

TITLE: Preparation of 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor for use in pharmaceutical compositions for the treatment of central nervous system (CNS) disorders

INVENTOR(S): Ahmed, Mahmood; Bromidge, Steven Mark; Forbes, Ian Thomson; Gribble, Andrew Derrick; Johnson, Christopher

Norbert; King, Francis David; Lightfoot, Andrew P.;
Macdonald, Gregor James; Moss, Stephen Frederick;
Thompson, Mervyn; Witty, David R.
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003062205 | A1 | 20030731 | WO 2002-EP14824 | 20021220 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1456178 | A1 | 20040915 | EP 2002-796752 | 20021220 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| JP 2005518414 | T | 20050623 | JP 2003-562087 | 20021220 |
| US 20050176759 | A1 | 20050811 | US 2004-499776 | 20040621 |

PRIORITY APPLN. INFO.:
GB 2001-30702 A 20011221
GB 2002-12398 A 20020529
WO 2002-EP14824 W 20021220

OTHER SOURCE(S): MARPAT 139:149539
GI



I



II

AB Sulfonylbenzazepines, such as I [R = aryl, biaryl; R1 = H, alkyl; R2 = H, OH, CN, NO2 CF3, OCF3, alkyl, alkyoxy, alkanoyl, cycloalkyl, alkylsulfonyl, alkylthio, carbamoyl, sulfamoyl, etc.], were prepared for therapeutic use modulating dopamine receptors. These benzazepines are useful for the treatment or prophylaxis of CNS or psychotic disorders, such as depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, bipolar disorder, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia and circadian rhythm disorders. Thus benzazepine derivative II was prepared by reaction of 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3- benzazepine-7-sulfonyl fluoride with 2-methyl-5-bromoaniline using t-BuLi in THF. The prepared benzazepines were tested for receptor binding activity for dopamine D2 and D3, 5-hydroxytryptamine 5-HT6,

5-HT2A, and 5-HT2C cloned human receptors and showed selectivity for the D2/D3 receptors.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:473266 CAPLUS Full-text
DOCUMENT NUMBER: 139:30862
TITLE: Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 464,344.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030114482 | A1 | 20030619 | US 2000-552823 | 20000420 <-- |
| US 6313168 | B1 | 20011106 | US 1999-464344 | 19991215 <-- |
| EP 1645271 | A1 | 20060412 | EP 2005-24409 | 20001213 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |
| CA 2407021 | A1 | 20011101 | CA 2001-2407021 | 20010419 <-- |
| WO 2001080894 | A2 | 20011101 | WO 2001-US12742 | 20010419 <-- |
| WO 2001080894 | A3 | 20020725 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1274456 | A2 | 20030115 | EP 2001-928654 | 20010419 <-- |
| EP 1274456 | B1 | 20041229 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2003531180 | T | 20031021 | JP 2001-577990 | 20010419 <-- |
| AT 285794 | T | 20050115 | AT 2001-928654 | 20010419 |
| AU 2001255488 | B2 | 20060727 | AU 2001-255488 | 20010419 |
| HK 1053053 | A1 | 20050610 | HK 2003-105084 | 20030714 |
| AU 2006233216 | A1 | 20061116 | AU 2006-233216 | 20061027 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1999-464344 | A2 | 19991215 |
| US 2000-552823 | A | 20000420 |
| EP 2000-986336 | A3 | 20001213 |
| WO 2001-US12742 | W | 20010419 |

OTHER SOURCE(S): MARPAT 139:30862

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis or osteoporosis, comprising administering therapeutically effective amts. of retinoid receptor antagonists or retinoid receptor agonists.

L6 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:319918 CAPLUS Full-text
DOCUMENT NUMBER: 138:338316
TITLE: Preparation of pelorol derivatives as SHIP 1 modulators
INVENTOR(S): Andersen, Raymond; Williams, David E.; Mui, Alice; Ong, Christopher; Krystal, Gerald
PATENT ASSIGNEE(S): The University of British Columbia, Can.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2003033517 | A1 | 20030424 | WO 2002-CA1550 | | 20021017 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2463136 | A1 | 20030424 | CA 2002-2463136 | | 20021017 <-- |
| AU 2002331507 | A1 | 20030428 | AU 2002-331507 | | 20021017 <-- |
| CA 2502293 | A1 | 20040429 | CA 2003-2502293 | | 20030423 |
| WO 2004035601 | A1 | 20040429 | WO 2003-CA571 | | 20030423 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2003218843 | A1 | 20040504 | AU 2003-218843 | | 20030423 |
| EP 1554304 | A1 | 20050720 | EP 2003-714589 | | 20030423 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| JP 2006506363 | T | 20060223 | JP 2004-543854 | | 20030423 |
| US 20040266865 | A1 | 20041230 | US 2004-825858 | | 20040416 |
| US 20080090909 | A1 | 20080417 | US 2007-871086 | | 20071011 |
| PRIORITY APPLN. INFO.: | | | US 2001-329506P | P | 20011017 |
| | | | AU 2002-331507 | A3 | 20021017 |
| | | | WO 2002-CA1550 | W | 20021017 |
| | | | WO 2003-CA571 | W | 20030423 |
| | | | US 2004-825858 | A3 | 20040416 |

OTHER SOURCE(S): MARPAT 138:338316
GI




I

AB The present invention includes the use of pelorol and related sesquiterpene compds., e.g. of formula I [Y = CH2, CH2CH2; R1-R4 = H, OH, alkoxy, alkoxycarbonyl, CH2OH, etc.], as modulators of SHIP 1 activity. This invention also provides novel sesquiterpene compds. capable of modulating SHIP 1 activity and methods of synthesis thereof. No examples are given. The effect of pelorol on macrophage nitric oxide production is measured.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:282399 CAPLUS Full-text

DOCUMENT NUMBER: 138:304302

TITLE: Preparation of amidine-substituted polycyclic compound prodrugs useful for selective inhibition of serine proteases of the coagulation cascade

INVENTOR(S): South, Michael S.; Webber, Ronald K.; Huang, Horng-chih; Toth, Mihaly V.; Moormann, Alan E.; Snyder, Jeffrey S.; Scholten, Jeffrey A.; Garland, Danny J.; Rueppel, Melvin L.; Neumann, William L.; Long, Scott; Wei, Huang; Trujillo, John; Parlow, John J.; Jones, Darin E.; Case, Brenda; Hayes, Michael J.; Zeng, Qingping

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 547 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003028729 | A2 | 20030410 | WO 2002-US31468 | 20021003 <-- |
| WO 2003028729 | A3 | 20040916 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2462601 | A1 | 20030410 | CA 2002-2462601 | 20021003 <-- |
| AU 2002337805 | A1 | 20030414 | AU 2002-337805 | 20021003 <-- |
| US 20030162776 | A1 | 20030828 | US 2002-263936 | 20021003 <-- |

| | | | | | |
|---|---|---|---|---|---|
| US 7105559 | B2 | 20060912 | | | |
| CA 2462645 | A1 | 20031113 | CA 2002-2462645 | | 20021003 <-- |
| WO 2003093242 | A2 | 20031113 | WO 2002-US31770 | | 20021003 <-- |
| WO 2003093242 | A3 | 20040429 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2002367752 | A1 | 20031117 | AU 2002-367752 | | 20021003 <-- |
| US 20040082585 | A1 | 20040429 | US 2002-263418 | | 20021003 |
| EP 1432687 | A2 | 20040630 | EP 2002-807360 | | 20021003 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | | |
| BR 2002013129 | A | 20040810 | BR 2002-13129 | | 20021003 |
| BR 2002013099 | A | 20041019 | BR 2002-13099 | | 20021003 |
| EP 1482940 | A2 | 20041208 | EP 2002-773700 | | 20021003 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | | |
| JP 2005509606 | T | 20050414 | JP 2003-532061 | | 20021003 |
| JP 2005525413 | T | 20050825 | JP 2004-501381 | | 20021003 |
| MX 2004003169 | A | 20040708 | MX 2004-3169 | | 20040402 |
| MX 2004003170 | A | 20040708 | MX 2004-3170 | | 20040402 |
| US 20050239860 | A1 | 20051027 | US 2005-159684 | | 20050623 |
| US 20050267123 | A1 | 20051201 | US 2005-159877 | | 20050623 |
| PRIORITY APPLN. INFO.: | | | US 2001-326721P | P | 20011003 |
| | | | US 2001-338623P | P | 20011024 |
| | | | US 2001-332857P | P | 20011106 |
| | | | US 2001-344957P | P | 20011107 |
| | | | US 2001-350052P | P | 20011107 |
| | | | US 2001-333292P | P | 20011114 |
| | | | US 2001-331891P | P | 20011121 |
| | | | US 2001-332014P | P | 20011121 |
| | | | US 2001-332104P | P | 20011121 |
| | | | US 2001-332107P | P | 20011121 |
| | | | US 2002-263637 | A1 | 20021003 |
| | | | US 2002-263936 | A1 | 20021003 |
| | | | WO 2002-US31468 | W | 20021003 |
| | | | WO 2002-US31770 | W | 20021003 |
| OTHER SOURCE(S): | MARPAT 138:304302 | | | | |
| GI | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to prodrug compds., comprising a 5- or 6-membered heterocyclic or aromatic ring substituted with a derivatized amidine (shown as I and II; variables defined below; e.g. N-[4-[(Z)-amino[(pyridin-2-ylmethoxy)imino]methyl]benzyl]-2-[6-[3-amino-5- (trifluoromethyl)phenyl]-3-(isopropylamino)-2-oxopyrazin-1(2H)- yl]acetamide (shown as III)), as well as compns. and methods useful for preventing and treating thrombotic conditions in mammals. The prodrug compds. of the present invention selectively inhibit certain serine proteases of the coagulation cascade (no data). For I: X = 5-

or 6-membered heterocyclic or aromatic ring, the ring atoms being X1, X2, X3, X4, and X5 for 5-membered heterocyclic rings and X1, X2, X3, X4, X5 and X6 for 6-membered heterocyclic or aromatic rings, wherein X2 is alpha to each of X1 and X3, X3 is alpha to each of X2 and X4, X4 is alpha to each of X3 and X5, X5 is alpha to X4 and alpha to X1 if X is a 5-membered ring or to X6 if X is a 6-membered ring, and X6, when present, is alpha to each of X1 and X5, wherein X1, X2, X3, X4, X5 and X6 are C, N, O or S. L1, L3 and L4 are linkages through which Z1, Z3, and Z4, resp., are covalently bonded to different ring atoms of the 5- or 6-membered heterocyclic or aromatic ring of X, wherein Z1 is covalently bonded to X1, Z3 is covalently bonded to X3, and Z4 is covalently bonded to X4, each of L1, L3 and L4 independently being a covalent bond or comprising ≥1 atoms through which Z1, Z3, and Z4 are covalently bonded to X1, X3 and X4, resp. Z1 is hydrocarbyl or substituted hydrocarbyl; Z3 = 5- or 6-membered heterocyclic or aromatic ring substituted with a derivatized amidine which, upon hydrolysis, oxidation, reduction or elimination yields an amidine group, and optionally further substituted with a halogen or hydroxy, the ring atoms of the 5- or 6-membered heterocyclic or aromatic ring of Z3 being C, S, N, or O. Z4 = 5- or 6-membered heterocyclic or carbocyclic ring having two substituents, R42 and R44, and two ring atoms each of which is in the beta position relative to the ring atom of Z4 through which Z4 is covalently bonded to X, wherein one of R42 and R44 is covalently bonded to one of said beta positions and the other of R42 and R44 is covalently bonded to the other of said beta positions, the ring atoms of the 5- or 6-membered heterocyclic or carbocyclic ring of Z4 being C, N, O, or S. R42 is amino; and R44 = H, hydrocarbyl, substituted hydrocarbyl, heterocyclo, halogen, or a (un)substituted heteroatom = N, O, S and P; provided, however, the derivatized amidine is other than amidine derivatized with tert-butoxycarbonyl. For II: each of X1, X2, X3, X4, X5 and X6 is C or N; X2 is a H bond acceptor; X9 is a direct bond or -(CH2)m- where m is 1 to 5. The metabolic stability and/or bioavailability of .apprx.20 examples of I/II are tabulated. Although the methods of preparation are not claimed, .apprx.160 example prepns. are included.

L6 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:150646 CAPLUS Full-text
DOCUMENT NUMBER: 138:195820
TITLE: Rinse-processing composition for processing silver halide color photographic material, processing apparatus and processing method
INVENTOR(S): Seki, Hioyuki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1286214 | A1 | 20030226 | EP 2002-18919 | 20020823 <-- |
| EP 1286214 | B1 | 20080312 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| US 20040043340 | A1 | 20040304 | US 2002-226180 | 20020823 |
| US 7163783 | B2 | 20070116 | | |

PRIORITY APPLN. INFO.: JP 2001-253095 A 20010823
US 2002-226180 T 20020823
OTHER SOURCE(S): MARPAT 138:195820

AB A rinse-processing composition of the present invention comprises a compound represented by R-(OC2H4)n-OH, (R = C8-13 alkyl; n = 10-30), but comprises neither aldehyde compds. nor hexamethylenetetramine derivs. The present invention relates to a processing method and a processing apparatus using such a rinse-processing composition

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:129387 CAPLUS Full-text

DOCUMENT NUMBER: 138:164054

TITLE: Methods and compounds for the use of retinoic acid antagonists and inverse agonists as male anti-fertility agents

INVENTOR(S): Klein, Elliott S.; Yuan, Yang-Dar; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 405,748, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| US 6521641 | B1 | 20030218 | US 2000-591253 | | 20000609 | <-- |
| US 20030144256 | A1 | 20030731 | US 2002-304665 | | 20021125 | <-- |
| US 20070054882 | A1 | 20070308 | US 2006-503635 | | 20060814 | |
| PRIORITY APPLN. INFO.: | | | US 1998-103507P | P | 19981008 | |
| | | | US 1999-405748 | B2 | 19990927 | |
| | | | US 2000-591253 | A1 | 20000609 | |
| | | | US 2002-304665 | B1 | 20021125 | |

OTHER SOURCE(S): MARPAT 138:164054

AB This continuation-in-part patent claims methods and compds. for the inhibition or prevention of spermatogenesis in a male mammal. The compds. claimed are antagonists or inverse agonists inhibiting the transcriptional activation of retinoic receptors RAR$\alpha$, RAR$\beta$ and/or RAR$\gamma$. Methods for the use of those compds. as anti-fertility agents to reduce or eliminate spermatozoa in the semen of male mammals to prevent conception are claimed.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:964331 CAPLUS Full-text

DOCUMENT NUMBER: 138:28938

TITLE: Dyeing composition for keratinous fibers comprising a particular dicationic diazo dye

INVENTOR(S): Vidal, Laurent; David, Herve

PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

WO 2002100834 A1 20021219 WO 2002-FR1980 20020610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
FR 2825703 A1 20021213 FR 2001-7613 20010611 <--
FR 2825703 B1 20080404
AU 2002319365 A1 20021223 AU 2002-319365 20020610 <--
EP 1399425 A1 20040324 EP 2002-748945 20020610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2002010995 A 20040608 BR 2002-10995 20020610
CN 1541207 A 20041027 CN 2002-815684 20020610
CN 100429203 C 20081029
JP 2005501134 T 20050113 JP 2003-503603 20020610
MX 2003011339 A 20040319 MX 2003-11339 20031208
US 20040244123 A1 20041209 US 2004-480202 20040728
US 7001436 B2 20060221
PRIORITY APPLN. INFO.: FR 2001-7613 A 20010611
WO 2002-FR1980 W 20020610
OTHER SOURCE(S): MARPAT 138:28938
AB The invention concerns a dyeing composition for dyeing keratinous fibers, in particular human keratinous fibers and more particularly hair, comprising a dicationic diazo dye as well as the dyeing method using same. Synthetic preparation of dicationic diazo dyes are described.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:868719 CAPLUS Full-text
DOCUMENT NUMBER: 137:346211
TITLE: Methods of treating hyperlipidemia by using retinoids as antagonists or inverse agonist of a retinoid receptor
INVENTOR(S): Yuan, Yang-Dar; Thacher, Scott M.; Klein, Elliot S.; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002089781 | A2 | 20021114 | WO 2002-US13253 | 20020426 <-- |
| WO 2002089781 | A3 | 20030327 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| US 20020193403 | A1 | 20021219 | US 2001-848159 | | 20010503 <-- |
| CA 2445504 | A1 | 20021114 | CA 2002-2445504 | | 20020426 <-- |
| AU 2002259030 | A1 | 20021118 | AU 2002-259030 | | 20020426 <-- |
| EP 1392284 | A2 | 20040303 | EP 2002-729013 | | 20020426 |
| EP 1392284 | B1 | 20080827 | | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | | |
|---|---|---|---|---|---|
| JP 2004532239 | T | 20041021 | JP 2002-586918 | | 20020426 |
| EP 1920771 | A2 | 20080514 | EP 2007-22682 | | 20020426 |
| EP 1920771 | A3 | 20080723 | | | |

R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR

| | | | | | |
|---|---|---|---|---|---|
| AT 406159 | T | 20080915 | AT 2002-729013 | | 20020426 |
| US 20050171151 | A1 | 20050804 | US 2004-16534 | | 20041217 |
| US 20080214652 | A1 | 20080904 | US 2008-72629 | | 20080227 |
| PRIORITY APPLN. INFO.: | | | US 2001-848159 | A | 20010503 |
| | | | EP 2002-729013 | A3 | 20020426 |
| | | | WO 2002-US13253 | W | 20020426 |
| | | | US 2004-16534 | B1 | 20041217 |

OTHER SOURCE(S): MARPAT 137:346211

AB The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:849441 CAPLUS Full-text

DOCUMENT NUMBER: 137:353048

TITLE: Combinations of pyridazinone aldose reductase inhibitors and cyclooxygenase-2 inhibitors

INVENTOR(S): Mylari, Banavara Lakshman

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002087584 | A1 | 20021107 | WO 2002-IB643 | 20020225 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2445871 | A1 | 20021107 | CA 2002-2445871 | 20020225 <-- |
| AU 2002236131 | A1 | 20021111 | AU 2002-236131 | 20020225 <-- |
| AU 2002236131 | B2 | 20050414 | | |
| HU 2003003920 | A2 | 20040301 | HU 2003-3920 | 20020225 |

| | | | | | | |
|---|---|---|---|---|---|---|
| HU 2003003920 | | A3 | 20040728 | | | |
| EP 1392310 | | A1 | 20040303 | EP 2002-702611 | | 20020225 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| CN 1505514 | | A | 20040616 | CN 2002-809037 | | 20020225 |
| JP 2004528344 | | T | 20040916 | JP 2002-584929 | | 20020225 |
| NZ 528150 | | A | 20050324 | NZ 2002-528150 | | 20020225 |
| TW 228415 | | B | 20050301 | TW 2002-91104376 | | 20020308 |
| US 20050004124 | | A1 | 20050106 | US 2002-137472 | | 20020430 |
| ZA 2003007204 | | A | 20040915 | ZA 2003-7204 | | 20030915 |
| US 20040198740 | | A1 | 20041007 | US 2004-810880 | | 20040325 |
| PRIORITY APPLN. INFO.: | | | | US 2001-287524P | P | 20010430 |
| | | | | WO 2002-IB643 | W | 20020225 |
| | | | | US 2002-137472 | A3 | 20020430 |

OTHER SOURCE(S): MARPAT 137:353048

GI




I

AB Pharmaceutical compns. and kits comprise pyridazinones I [A = S, S(O), SO2; R1, R2 = H, Me; R3 = heterocyclic, heterocyclylalkyl, amino, CH2CH(OH)Ar, CH2COAr, arylamino, aralkyl; Ar = (un)substituted Ph, naphthyl] and cyclooxygenase-2 inhibitors for treatment or prevention of certain complications arising from diabetes mellitus and cardiac tissue ischemia in mammals (no data). Thus, 2-mercaptoindole was treated with 2-chloro-6-methoxypyridazine, followed by oxidation to the sulfone and demethylation to give 6-(indole-2-sulfonyl)-2H-pyridazin-3-one.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:793584 CAPLUS Full-text

DOCUMENT NUMBER: 137:310696

TITLE: Preparation of N-hydroxyphenylacetamides as peptide deformylase inhibitors

INVENTOR(S): Bhat, Ajita; Christensen, Siegfried B., IV; Frazee, James S.; Head, Martha S.; Leber, Jack Dale; Li, Mei

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002081426 | A1 | 20021017 | WO 2002-US10506 | 20020404 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| AU 2002252585 | A1 | 20021021 | AU 2002-252585 | 20020404 <-- |
| EP 1383729 | A1 | 20040128 | EP 2002-721667 | 20020404 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004527530 | T | 20040909 | JP 2002-579414 | 20020404 |
| US 20040267015 | A1 | 20041230 | US 2003-473104 | 20030929 |
| PRIORITY APPLN. INFO.: | | | US 2001-281613P P | 20010405 |
| | | | WO 2002-US10506 W | 20020404 |

OTHER SOURCE(S): MARPAT 137:310696
GI



I

AB PDF inhibitors I [X = CO2(C1-6-alkyl), OR1, NR1R6, CONR1R6, C(:O)R6; R1 = H, (un)substituted C1-6-alkyl, Ar-(C1-6-alkyl); R1R6 = 5- or 6-membered cyclic system which may contain an O or (un)substituted N; R2 = I, Br, Cl, CHMe2, CMe3; R3 = H, I, Br, Cl,CHMe2, CMe3, ZR8; Z = O, N, NC(:O), C(:O)N, SO2N, CONHSO2, CH2; R6 = H, Me; R8 = (un)substituted C1-4-alkyl; Ar = (un)substituted Ph, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, tetrazolyl, imidazolyl, benzofuranyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidinyl] and novel methods for their use are provided. Thus, I (X = OC6H4OH, R2 = R3 = I) was prepared from 3,5-diiodothyroacetic acid via esterification with MeOH containing H2SO4 followed by amidation with NH2OH in aqueous dioxane. I was tested for PDF inhibition and antimicrobial activity (MIC = 0.06 - 64 mcg/mL).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:755213 CAPLUS Full-text
DOCUMENT NUMBER: 137:279206
TITLE: Preparation of sulfenyl, sulfinyl and sulfonyl pyridazinone aldose reductase inhibitors for treating/preventing diabetic complications
INVENTOR(S): Mylari, Banavara L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| US 20020143017 | A1 | 20021003 | US 2002-104664 | | 20020321 | <-- |
| US 6579879 | B2 | 20030617 | | | | |
| CA 2442476 | A1 | 20021010 | CA 2002-2442476 | | 20020131 | <-- |
| WO 2002079198 | A1 | 20021010 | WO 2002-IB320 | | 20020131 | <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | | |
| AU 2002226634 | A1 | 20021015 | AU 2002-226634 | | 20020131 | <-- |
| AU 2002226634 | B2 | 20070125 | | | | |
| EP 1373259 | A1 | 20040102 | EP 2002-716247 | | 20020131 | |
| EP 1373259 | B1 | 20041229 | | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| EE 200300470 | A | 20040216 | EE 2003-470 | | 20020131 | |
| HU 2003003644 | A2 | 20040301 | HU 2003-3644 | | 20020131 | |
| HU 2003003644 | A3 | 20080630 | | | | |
| BR 2002008571 | A | 20040323 | BR 2002-8571 | | 20020131 | |
| NZ 528406 | A | 20040326 | NZ 2002-528406 | | 20020131 | |
| CN 1500087 | A | 20040526 | CN 2002-807600 | | 20020131 | |
| CN 1215067 | C | 20050817 | | | | |
| JP 2004528319 | T | 20040916 | JP 2002-577823 | | 20020131 | |
| EP 1491540 | A1 | 20041229 | EP 2004-23149 | | 20020131 | |
| EP 1491540 | B1 | 20061213 | | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| EP 1491541 | A1 | 20041229 | EP 2004-23150 | | 20020131 | |
| EP 1491541 | B1 | 20070124 | | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | | |
| AT 286049 | T | 20050115 | AT 2002-716247 | | 20020131 | |
| PT 1373259 | T | 20050331 | PT 2002-716247 | | 20020131 | |
| ES 2231681 | T3 | 20050516 | ES 2002-716247 | | 20020131 | |
| DE 60202452 | C5 | 20061123 | DE 2002-60202452 | | 20020131 | |
| AT 348100 | T | 20070115 | AT 2004-23149 | | 20020131 | |
| AT 352551 | T | 20070215 | AT 2004-23150 | | 20020131 | |
| ES 2274369 | T3 | 20070516 | ES 2004-23149 | | 20020131 | |
| TW 245762 | B | 20051221 | TW 2002-91106386 | | 20020329 | |
| US 20030162784 | A1 | 20030828 | US 2003-370895 | | 20030220 | <-- |
| US 6849629 | B2 | 20050201 | | | | |
| ZA 2003004671 | A | 20040625 | ZA 2003-4671 | | 20030617 | |
| IN 2003MN00639 | A | 20050318 | IN 2003-MN639 | | 20030624 | |
| BG 108179 | A | 20040930 | BG 2003-108179 | | 20030917 | |
| NO 2003004345 | A | 20030929 | NO 2003-4345 | | 20030929 | <-- |
| MX 2003008850 | A | 20031204 | MX 2003-8850 | | 20030929 | <-- |
| HK 1061678 | A1 | 20051104 | HK 2004-104538 | | 20040624 | |
| US 20050113381 | A1 | 20050526 | US 2004-968759 | | 20041018 | |
| PRIORITY APPLN. INFO.: | | | US 2001-280051P | P | 20010330 | |
| | | | EP 2002-716247 | A3 | 20020131 | |
| | | | WO 2002-IB320 | W | 20020131 | |

US 2002-104664 A3 20020321
US 2003-370895 A3 20030220

OTHER SOURCE(S): MARPAT 137:279206

GI



I

AB The present invention relates to novel pyridazinone compds. (shown as I; variables partially described below; e.g. 6-(2-indolylsulfonyl)-2H-pyridazin-3-one), pharmaceutical compns. comprising those compds. and to methods of using such compds. and compns. to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compns. and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compns. or kits to treat or prevent the above diabetic complications in mammals. This invention also relates to other combinations with the ARIs of this invention, including combinations with adenosine agonists; NHE-1 inhibitors; glycogen phosphorylase inhibitors; selective serotonin reuptake inhibitors; GABA agonists; antihypertensive agents; 3-hydroxy-3-methylglutaryl CoA reductase inhibitors; phosphodiesterase-5 inhibitors; and to glucose lowering agents. In I, A is S, SO or SO2; R1 and R2 are each independently H or Me; R3 is heteroaryl, -CHR4(heteroaryl) or NR6R7; R4 is H or (C1-C3)alkyl; R6 is (C1-C6)alkyl, aryl or heteroaryl; R7 is heteroaryl. No pharmacol. data is included. Although the methods of preparation are not claimed, .apprx.50 example prepns. are included.

L6 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:798081 CAPLUS Full-text
DOCUMENT NUMBER: 135:339297
TITLE: Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001080894 | A2 | 20011101 | WO 2001-US12742 | 20010419 <-- |
| WO 2001080894 | A3 | 20020725 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 20030114482 | A1 | 20030619 | US 2000-552823 | 20000420 <-- |
| CA 2407021 | A1 | 20011101 | CA 2001-2407021 | 20010419 <-- |
| EP 1274456 | A2 | 20030115 | EP 2001-928654 | 20010419 <-- |
| EP 1274456 | B1 | 20041229 | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|---|---|---|---|---|
| JP 2003531180 | T | 20031021 | JP 2001-577990 | 20010419 <-- |
| AT 285794 | T | 20050115 | AT 2001-928654 | 20010419 |
| AU 2001255488 | B2 | 20060727 | AU 2001-255488 | 20010419 |
| HK 1053053 | A1 | 20050610 | HK 2003-105084 | 20030714 |
| AU 2006233216 | A1 | 20061116 | AU 2006-233216 | 20061027 |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 2000-552823 | A | 20000420 |
| | US 1999-464344 | A2 | 19991215 |
| | WO 2001-US12742 | W | 20010419 |

OTHER SOURCE(S): MARPAT 135:339297

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis or osteoporosis, comprising administering therapeutically effective amts. of retinoid receptor antagonists or retinoid receptor agonists.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:693315 CAPLUS Full-text
DOCUMENT NUMBER: 135:242245
TITLE: Preparation of 6-aminoalkyl-2-heterocyclyl-4-phenyldihydropyrimidine-5-carboxylates as antiviral agents for treatment of hepatitis B infection.
INVENTOR(S): Goldmann, Siegfried; Stoltefuss, Juergen; Niewoehner, Ulrich; Schlemmer, Karl-Heinz; Keldenich, Joerg; Paessens, Arnold; Graef, Erwin; Weber, Olaf; Deres, Karl
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001068641 | A1 | 20010920 | WO 2001-EP2443 | 20010305 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
DE 10013126 A1 20010920 DE 2000-10013126 20000317 <--
PRIORITY APPLN. INFO.: DE 2000-10013126 A 20000317
OTHER SOURCE(S): MARPAT 135:242245
GI



I



II

AB Title compds. I and II [R1 = (substituted) pyridyl, pyrimidyl, pyrazinyl, thiazolyl; R2 = (substituted) aryl, heteroaryl; R3 = (substituted) (O-, S-interrupted) alkyl; R4 = (substituted) alkyl, aryl, heteroaryl, etc.; R5 = H, (substituted) (interrupted) alkyl, heteroaryl, etc.; R4R5 = (substituted) (interrupted) cycloalkyl, etc.; X = (substituted) (O-interrupted) alkylene], were prepared Thus, Me (R)-6-bromomethyl-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)- 1,4-dihydropyrimidine-5-carboxylate (preparation given) was stirred with Na2CO3 and 1-cyclopropylpiperazine dihydrochloride in MeOH for 2 h at room temperature to give 87.6% Me (R)-4-(2-chloro-4-fluorophenyl)-6-[(4-cyclopropyl-1- piperazinyl)methyl]-2-(2,3-difluoro-2-pyridinyl)-1,4-dihydropyrimidine-5- carboxylate. Several title compds. inhibited intra- or extracellular DNA of hepatitis B virus-producing Hep G2.2.15-cells with inhibited with IC50 = 0.015-0.08 μM.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:472731 CAPLUS Full-text
DOCUMENT NUMBER: 135:61439
TITLE: Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
INVENTOR(S): Leblanc, Yves; Dufresne, Claude; Gauthier, Jacques Yves; Lau, Cheuk Kun; Li, Chun Sing; Roy, Patrick; Therien, Michel; Scheigetz, John; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001046206 | A1 | 20010628 | WO 2000-CA1550 | 20001221 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2393367 | A1 | 20010628 | CA 2000-2393367 | 20001221 <-- |
| US 20020058644 | A1 | 20020516 | US 2000-745211 | 20001221 <-- |
| US 6486142 | B2 | 20021126 | | |
| EP 1244678 | A1 | 20021002 | EP 2000-986935 | 20001221 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2003518130 | T | 20030603 | JP 2001-547115 | 20001221 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-171520P | P 19991222 |
| | | | WO 2000-CA1550 | W 20001221 |

OTHER SOURCE(S): MARPAT 135:61439

AB Twenty-four antidiabetic and antiobesity title compds. were prepared by standard methods. Among the compds. prepared were: 2-bromo-4-[2-phenyl-2-(5-phenyl-1,2,4-oxadiazol-3- yl)ethyl]phenyl(difluoro)methylphosphonic acid and [(isopropoxycarbonyl)oxy]methyl hydrogen [2-bromo-4-(3-oxo-2,3-diphenyl)phenyl](difluoro)methyl phosphate. The invention also encompasses pharmaceutical compns. and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:452848 CAPLUS Full-text
DOCUMENT NUMBER: 135:41045
TITLE: Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001043732 | A2 | 20010621 | WO 2000-US33697 | 20001213 <-- |
| WO 2001043732 | A3 | 20020321 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6313168 | B1 | 20011106 | US 1999-464344 | 19991215 <-- |
| CA 2394210 | A1 | 20010621 | CA 2000-2394210 | 20001213 <-- |
| EP 1248602 | A2 | 20021016 | EP 2000-986336 | 20001213 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2003519103 | T | 20030617 | JP 2001-544671 | 20001213 <-- |
| AU 784189 | B2 | 20060216 | AU 2001-22593 | 20001213 |
| EP 1645271 | A1 | 20060412 | EP 2005-24409 | 20001213 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |

PRIORITY APPLN. INFO.: US 1999-464344 A 19991215
EP 2000-986336 A3 20001213
WO 2000-US33697 W 20001213

OTHER SOURCE(S): MARPAT 135:41045

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis, comprising administering therapeutically effective amts. of retinoid receptor antagonists. AG1-X2 ion exchange beads were soaked for 1 h in a solution of 4-[[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2- naphthalenyl]ethynyl]-benzoic acid (AGN 109) and implanted in the vicinity of the prospective humeral mesenchymal condensation in stage 21-22 chick embryos and determined whether humerus development had been impaired by day 10 in vivo. AGN 109-containing beads showed striking effects on humerus development.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 39 CAPLUS 
ACCESSION NUMBER: 2001:396864 CAPLUS Full-text
DOCUMENT NUMBER: 135:19632
TITLE: Preparation of pyrazolyl- and pyrrolylalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
INVENTOR(S): Momose, Yu; Maekawa, Tsuyoshi; Odaka, Hiroyuki; Kimura, Hiroyuki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 375 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001038325 | A1 | 20010531 | WO 2000-JP7877 | 20001109 <-- |
| W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2390923 | A1 | 20010531 | CA 2000-2390923 | 20001109 <-- |
| JP 2001226350 | A | 20010821 | JP 2000-347462 | 20001109 <-- |
| JP 3723071 | B2 | 20051207 | | |
| BR 2000015466 | A | 20020806 | BR 2000-15466 | 20001109 <-- |
| EP 1228067 | A1 | 20020807 | EP 2000-974857 | 20001109 <-- |
| EP 1228067 | B1 | 20040714 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| HU 2002003165 | A2 | 20030128 | HU 2002-3165 | 20001109 <-- |
| HU 2002003165 | A3 | 20040329 | | |
| JP 2003137865 | A | 20030514 | JP 2002-315096 | 20001109 <-- |
| NZ 519238 | A | 20031128 | NZ 2000-519238 | 20001109 <-- |
| AT 271049 | T | 20040715 | AT 2000-974857 | 20001109 |
| EP 1457490 | A1 | 20040915 | EP 2004-76508 | 20001109 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| PT 1228067 | T | 20041130 | PT 2000-974857 | 20001109 |
| ES 2225252 | T3 | 20050316 | ES 2000-974857 | 20001109 |

| | | | | | | |
|---|---|---|---|---|---|---|
| AU 780948 | B2 | 20050428 | AU 2001-13031 | | 20001109 | |
| RU 2252939 | C2 | 20050527 | RU 2002-115263 | | 20001109 | |
| CN 1260227 | C | 20060621 | CN 2000-817467 | | 20001109 | |
| NO 2002002108 | A | 20020708 | NO 2002-2108 | | 20020502 | <-- |
| MX 2002004647 | A | 20021031 | MX 2002-4647 | | 20020509 | <-- |
| US 7179823 | B1 | 20070220 | US 2002-129702 | | 20020509 | |
| IN 2002KN00645 | A | 20050311 | IN 2002-KN645 | | 20020513 | |
| ZA 2002003824 | A | 20031015 | ZA 2002-3824 | | 20020514 | <-- |
| HK 1045991 | A1 | 20041210 | HK 2002-106297 | | 20020827 | |
| PRIORITY APPLN. INFO.: | | | JP 1999-320317 | A | 19991110 | |
| | | | JP 1999-352237 | A | 19991210 | |
| | | | JP 1999-352236 | A | 19991210 | |
| | | | EP 2000-974857 | A3 | 20001109 | |
| | | | JP 2000-347462 | A3 | 20001109 | |
| | | | WO 2000-JP7877 | W | 20001109 | |

OTHER SOURCE(S): MARPAT 135:19632

GI



I



II

AB Title compds. (I) [wherein R1 = (un)substituted hydrocarbon or heterocycle; X = bond, O, S, CO, CS, CR4(OR5), or NR6; R4 and R6 = independently H or (un)substituted hydrocarbon; R5 = H or hydroxyl protective group; m = 0-3; Y = O, S, SO, SO2, NR7, CONR7, or NR7CO; R7 = H or (un)substituted hydrocarbon; A = (un)substituted aromatic ring; n = 1-8; B = (un)substituted N-containing 5-membered heterocycle; X1 = bond, O, S, SO, SO2, OSO2, or NR16; R16 = H or (un)substituted hydrocarbon; R2 = H or (un)substituted hydrocarbon or heterocycle; W = bond or hydrocarbon; R3 = OR8 or NR9R10; R8 = H or (un)substituted hydrocarbon; R9 and R10 = independently H or (un)substituted hydrocarbon or heterocycle; or R9 and R10 together with the N to which they are attached may form a ring] were prepared as retinoid-related receptor function regulating agents or insulin resistance improving agents. For example, Et 3-[1-(4-hydroxybenzyl)-4-phenyl-3-pyrrolyl]propionate and 4-chloromethyl-5-methyl-2-(2-thienyl)oxazole were coupled in the presence of K2CO3 in DMF and treated with HCl to give II (77%). At a concentration of 0.001%, II reduced hypoglycemic and hypolipidemic action by 48% and 70%, resp., lowered total cholesterol by 16%, and increased the plasma anti-arteriosclerosis index by 12% compared to non-treatment groups of mice. In addition, II showed potent PPARγ-RXRα heterodimer ligand activity with EC50 of 1.5 nM. I are useful for the prevention or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, and arteriosclerosis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:247339 CAPLUS Full-text
DOCUMENT NUMBER: 134:261280
TITLE: Azepinoindolone derivatives as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Lubisch, Wilfried; Kock, Michael; Hoeger, Thomas; Grandel, Roland; Mueller, Reinhold; Schult, Sabine
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001023390 | A2 | 20010405 | WO 2000-EP9024 | 20000915 <-- |
| WO 2001023390 | A3 | 20011227 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 19946289 | A1 | 20010329 | DE 1999-19946289 | 19990928 <-- |
| DE 10039610 | A1 | 20020228 | DE 2000-10039610 | 20000809 <-- |
| CA 2352194 | A1 | 20010405 | CA 2000-2352194 | 20000915 <-- |
| BR 2000007174 | A | 20010904 | BR 2000-7174 | 20000915 <-- |
| EP 1183259 | A2 | 20020306 | EP 2000-974379 | 20000915 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| HU 2001004917 | A2 | 20020429 | HU 2001-4917 | 20000915 <-- |
| HU 2001004917 | A3 | 20021228 | | |
| JP 2003510328 | T | 20030318 | JP 2001-526542 | 20000915 <-- |
| MX 2001005199 | A | 20020311 | MX 2001-5199 | 20010524 <-- |
| NO 2001002567 | A | 20010625 | NO 2001-2567 | 20010525 <-- |
| IN 2001CN00726 | A | 20050304 | IN 2001-CN726 | 20010525 |
| BG 105650 | A | 20020228 | BG 2001-105650 | 20010626 <-- |

PRIORITY APPLN. INFO.:
DE 1999-19946289 A 19990928
DE 2000-10039610 A 20000809
WO 2000-EP9024 W 20000915

OTHER SOURCE(S): MARPAT 134:261280
AB Enantiomeric and diastereomeric forms and prodrugs of azepinoindolone derivs. such as 2-(4-(4-n-propylpiperazin-1-yl)phenyl)-1,3,4,5-tetrahydro- 6H-azepino[5,4,3-c,d]indol-6-one are useful as poly(ADP-ribose) polymerase inhibitors. The effectiveness of the title compds. in inhibiting poly(ADP-ribose) polymerase was demonstrated.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:185763 CAPLUS Full-text
DOCUMENT NUMBER: 134:207967
TITLE: Preparation of electronically tuned ligands

INVENTOR(S): Busacca, Carl
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001018012 | A1 | 20010315 | WO 2000-US24162 | 20000905 <-- |
| W: CA, JP, MX | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2382163 | A1 | 20010315 | CA 2000-2382163 | 20000905 <-- |
| US 6316620 | B1 | 20011113 | US 2000-655115 | 20000905 <-- |
| EP 1218388 | A1 | 20020703 | EP 2000-959804 | 20000905 <-- |
| EP 1218388 | B1 | 20040128 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| JP 2003508538 | T | 20030304 | JP 2001-522235 | 20000905 <-- |
| AT 258556 | T | 20040215 | AT 2000-959804 | 20000905 |
| PT 1218388 | T | 20040531 | PT 2000-959804 | 20000905 |
| ES 2213600 | T3 | 20040901 | ES 2000-959804 | 20000905 |
| MX 2002002353 | A | 20020730 | MX 2002-2353 | 20020304 <-- |

PRIORITY APPLN. INFO.: US 1999-152909P P 19990908
WO 2000-US24162 W 20000905
OTHER SOURCE(S): MARPAT 134:207967
GI




I

AB The preparation of phosphino- or arsinoamidines I (M = P, As; X, Y, Z = independently selected from H, alkyl, aryl (pendant or fused), halo, C1-10 alkoxy, cyano, nitro, amino, alkylamino, dialkylamino, CO2H, -CO(lower alkoxy), -CO(lower alkyl), -NCOH, -NCO(lower alkyl), NSO2(alkyl), -NSO2(aryl), hydroxy, alkyl, sulfonoxyalkyl, sulfonoxyaryl, alkoxyalkyl; R1 = H, C1-10 alkyl, branched alkyl or cycloalkyl; aryl, substituted aryl, heteroaryl or substituted heteroaryl where the heteroatoms are N, O, S, acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, or SO2R4; R4 = alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl groups in direct attachment, with the provisos that R2 and R3 can be the same or different and are H, aryl, heteroaryl as defined above, substituted aryl or

heteroaryl as defined (with substituents as defined below), alkyl, branched alkyl, cycloalkyl, benzyl, substituted benzyl, with substituents as defined for aryl, or R2 and R3 together may form a fused carbocyclic ring, Ring B is an imidazoline ring or a tetrahydropyrimidine ring), useful as cocatalyst for stereoselective synthesis, is described. Thus, preparation of title ligand cocatalyst 2-(2'-diphenylphosphinophenyl)-3-(2''-naphthoyl)-(4S,5S)-diphenyl-4,5- dihydroimidazole, is described in four steps starting from 2-FC6H4CONH2; the use of prepared ligand as cocatalyst for asym. Heck reaction is also described.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:78220 CAPLUS Full-text
DOCUMENT NUMBER: 134:125939
TITLE: The use of retinoid receptor antagonists in the treatment of prostate carcinoma
INVENTOR(S): Chandraratna, Roshantha A.; Brown, Geoffrey
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001007028 | A2 | 20010201 | WO 2000-US19849 | 20000721 <-- |
| WO 2001007028 | A3 | 20010830 | | |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-145287P P 19990723
OTHER SOURCE(S): MARPAT 134:125939
AB Methods for treating prostate cancer comprise administering a therapeutically effective amount of a retinoid receptor antagonist. In addition, the invention provides methods of inhibiting the growth of a prostate carcinoma cell or tumor, the method comprising contacting the cell or tumor with an effective amount of a retinoid receptor antagonist.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:63991 CAPLUS Full-text
DOCUMENT NUMBER: 134:115959
TITLE: Preparation of novel 4,4-diphenylpiperidines for the treatment of chemokine receptor related diseases and conditions
INVENTOR(S): Baxter, Andrew John Gilby; Brough, Stephen John; McInally, Thomas
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001005782 | A1 | 20010125 | WO 2000-GB2756 | 20000718 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2378084 | A1 | 20010125 | CA 2000-2378084 | 20000718 <-- |
| BR 2000012610 | A | 20020409 | BR 2000-12610 | 20000718 <-- |
| EP 1202984 | A1 | 20020508 | EP 2000-946134 | 20000718 <-- |
| EP 1202984 | B1 | 20030305 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| JP 2003505383 | T | 20030212 | JP 2001-511441 | 20000718 <-- |
| AT 233754 | T | 20030315 | AT 2000-946134 | 20000718 <-- |
| NZ 516606 | A | 20030926 | NZ 2000-516606 | 20000718 <-- |
| AU 771344 | B2 | 20040318 | AU 2000-60016 | 20000718 |
| CN 1152873 | C | 20040609 | CN 2000-810670 | 20000718 |
| US 6566376 | B1 | 20030520 | US 2000-623744 | 20000908 <-- |
| ZA 2001010540 | A | 20030324 | ZA 2001-10540 | 20011221 <-- |
| NO 2002000282 | A | 20020321 | NO 2002-282 | 20020118 <-- |
| MX 2002000671 | A | 20020702 | MX 2002-671 | 20020118 <-- |

PRIORITY APPLN. INFO.: SE 1999-2765 A 19990721
WO 2000-GB2756 W 20000718

OTHER SOURCE(S): MARPAT 134:115959
GI




I




II

AB The title compds. [I; R1, R2 = (un)substituted Ph; R3 = halo, NO2, alkyl, etc.; n = 0-3; R4 = H, OH, NR10R11; A = CO, CH2, a bond; Q = alkylene; U, W and X = (un)substituted C, N; V = (un)substituted N, O; Y = alkylene, CO; R10,

R11 = H, alkyl, unsatd. alkyl, etc.; NR10R11 = (un)substituted 4-8 membered saturated azacyclic ring] and their pharmaceutically acceptable salts, useful in therapy, especially for the treatment of chemokine receptor related diseases and conditions (no data), were prepared E.g., a 2-step synthesis of 4,4-diphenylpiperidine II was given.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:686089 CAPLUS Full-text

DOCUMENT NUMBER: 133:268546

TITLE: Group VIII metal complexes with phosphinamidite ligands as catalysts for hydroformylation or hydrocyanation of olefins

INVENTOR(S): Ahlers, Wolfgang; Maas, Heiko; Roeper, Michael

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 19913352 | A1 | 20000928 | DE 1999-19913352 | 19990324 <-- |
| WO 2000056451 | A1 | 20000928 | WO 2000-EP2610 | 20000323 <-- |
| W: CN, JP, US | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP 1163051 | A1 | 20011219 | EP 2000-918832 | 20000323 <-- |
| EP 1163051 | B1 | 20041110 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002539920 | T | 20021126 | JP 2000-606345 | 20000323 <-- |
| US 6852661 | B1 | 20050208 | US 2001-937310 | 20010924 |

PRIORITY APPLN. INFO.: DE 1999-19913352 A 19990324
WO 2000-EP2610 W 20000323

OTHER SOURCE(S): MARPAT 133:268546

GI




I

AB Group VIII metal complexes with mono- or multidentate phosphinamidite ligands of specified structure are used as catalysts for hydroformylation or hydrocyanation of olefins, e.g., 1-octene or 3-pentenenitrile. For example, chlorination of biphenyl-2-ol with PCl3 in the presence of ZnCl2 gave 69% 6-chloro-(6H)-dibenz[c,e][1,2]oxaphosphorin. Stirring of the latter with K-metalated pyrrole for 12 h at ambient temperature in THF gave 50% of a title

ligand I. Hydroformylation of 22.5 g 1-octene with synthesis gas (CO/H = 1:1; 40 bar) in the presence of 123 mg (acac)Rh(CO)2 (acacH = acetylacetone) and 680 mg I gave nonanal isomers with 96% selectivity.

L6 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:441769 CAPLUS Full-text
DOCUMENT NUMBER: 133:73851
TITLE: Preparation of novel herbicidally active benzoyl derivatives
INVENTOR(S): Schaetzer, Juergen; De Mesmaeker, Alain; Lee, Shy-Fuh
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000037437 | A1 | 20000629 | WO 1999-EP10128 | 19991220 <-- |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| BR 9916396 | A | 20010911 | BR 1999-16396 | 19991220 <-- |
| EP 1140811 | A1 | 20011010 | EP 1999-963584 | 19991220 <-- |
| EP 1140811 | B1 | 20060802 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY | | | | |
| AT 334961 | T | 20060815 | AT 1999-963584 | 19991220 |
| CN 100386313 | C | 20080507 | CN 1999-814885 | 19991220 |
| US 20020165096 | A1 | 20021107 | US 2001-886896 | 20010621 <-- |
| US 6599861 | B2 | 20030729 | | |
| US 20030236167 | A1 | 20031225 | US 2003-454966 | 20030605 <-- |
| US 7265230 | B2 | 20070904 | | |
| US 20070265165 | A1 | 20071115 | US 2007-828598 | 20070726 |

PRIORITY APPLN. INFO.:
CH 1998-2521 A 19981221
WO 1999-EP10128 W 19991220
US 2001-886896 A3 20010621
US 2003-454966 A3 20030605

OTHER SOURCE(S): MARPAT 133:73851
GI



I

AB The title compds. [I; X = CH2OMe, CH2OEt, CH2OH, etc.; R1, R2 = halo, CN, NO2, etc.; R3 = H, alkyl, halo; Q = 5,6-dihydro-5-hydroxy-3-oxo-2,6,6-trimethyl-2H-[1,2]oxazin-4-yl, 4-hydroxy-2-oxo-bicyclo[3.2.1]oct-3-en-3-yl, etc.] which are eminently suitable for use as herbicides, were prepared E.g., a 2-step synthesis of I [X = CH2OMe; R1 = Me; R2 = SO2Me; R3 = H; Q = 5,6-dihydro-5-hydroxy-3-oxo-2,6,6-trimethyl-2H-[1,2]oxazin-4-yl] which showed good herbicidal action against Setaria and Cyperus in pre-emergent and post-emergent action tests at 2000 g AS/ha, was given.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:240931 CAPLUS Full-text

DOCUMENT NUMBER: 132:274821

TITLE: Male antifertility agents

INVENTOR(S): Klein, Elliott S.; Yuan, Yang-Dar; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000019990 | A2 | 20000413 | WO 1999-US22222 | 19990924 <-- |
| WO 2000019990 | A3 | 20000720 | | |
| W: AU, CA, JP | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2346687 | A1 | 20000413 | CA 1999-2346687 | 19990924 <-- |
| AU 9961623 | A | 20000426 | AU 1999-61623 | 19990924 <-- |
| AU 757448 | B2 | 20030220 | | |
| EP 1119350 | A2 | 20010801 | EP 1999-948451 | 19990924 <-- |
| EP 1119350 | B1 | 20050223 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002526405 | T | 20020820 | JP 2000-573351 | 19990924 <-- |
| AT 289507 | T | 20050315 | AT 1999-948451 | 19990924 |

PRIORITY APPLN. INFO.: US 1998-103507P P 19981008
WO 1999-US22222 W 19990924

OTHER SOURCE(S): MARPAT 132:274821

GI




I

AB Methods and compns. for inhibiting or preventing spermatogenesis in a male mammal are disclosed. AGN 194310 (I) was prepared and orally administered to rats and was not toxic and expts. showed that daily oral delivery of this RAR antagonist was sufficient to cause spermatogenic arrest.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:84792 CAPLUS Full-text

DOCUMENT NUMBER: 132:122612

TITLE: Preparation of benzoxazole derivatives for inhibiting the interaction between VCAM-1 and/or fibronectin and the integrin receptor VLA-4

INVENTOR(S): Brittain, David Robert; Johnstone, Craig; Davies, Gareth Morse; Large, Michael Stewart

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000005224 | A2 | 20000203 | WO 1999-GB2342 | 19990720 <-- |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9950530 | A | 20000214 | AU 1999-50530 | 19990720 <-- |
| EP 1144393 | A2 | 20011017 | EP 1999-934897 | 19990720 <-- |
| EP 1144393 | A3 | 20020911 | | |
| EP 1144393 | B1 | 20040211 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002521376 | T | 20020716 | JP 2000-561180 | 19990720 <-- |
| AT 259359 | T | 20040215 | AT 1999-934897 | 19990720 |
| US 6441012 | B1 | 20020827 | US 2001-744331 | 20010123 <-- |

PRIORITY APPLN. INFO.: GB 1998-15971 A 19980723
GB 1998-15973 A 19980723

WO 1999-GB2342 W 19990720

OTHER SOURCE(S): MARPAT 132:122612

GI



I



II

AB The title compds. [I; A = (un)substituted bicyclic heteroaryl; B = linker group connecting group A to group D and comprising (un)substituted 3 or 4 atom linker where each atom is independently selected from C, O, N and S; C = (un)substituted aryl, mono or bicyclic heteroaryl; D = (un)substituted aryl, heteroaryl; R1 = H, alkyl, alkanoyl, alkoxycarbonyl; R2-R5 = H, alkyl, (un)substituted aryl, etc.; two of R2-R5 can be taken together to form a 3-7 membered ring; R6 = acidic functional group; r, s = 0-1 with the proviso that r and s cannot both be 0], useful for treating multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease, psoriasis, atherosclerosis, transplant rejection, inflammatory bowel disease, insulin-dependent diabetes and glomerulonephritis, were prepared E.g., a multi-step synthesis of benzoxazole II was given. Compds. I are effective at 0.1-15 mg/kg/day.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:784149 CAPLUS Full-text

DOCUMENT NUMBER: 132:36180

TITLE: Macromolecular photoinitiators and their applications

INVENTOR(S): Asakura, Toshikage; Ohwa, Masaki; Yamato, Hitoshi; Tatsumi, Asako

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9962961 | A1 | 19991209 | WO 1999-EP3458 | 19990520 <-- |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| AU 9943639 | A | 19991220 | AU 1999-43639 | | 19990520 <-- |
| EP 1086145 | A1 | 20010328 | EP 1999-926340 | | 19990520 <-- |
| EP 1086145 | B1 | 20040512 | | | |
| R: CH, DE, FR, GB, IT, LI | | | | | |
| JP 2002517522 | T | 20020618 | JP 2000-552170 | | 19990520 <-- |
| US 6458864 | B1 | 20021001 | US 2000-701457 | | 20001127 <-- |
| PRIORITY APPLN. INFO.: | | | EP 1998-810501 | A | 19980529 |
| | | | WO 1999-EP3458 | W | 19990520 |

OTHER SOURCE(S): MARPAT 132:36180
GI



I

AB The title photoinitiators are prepared by thermal polymerization of a monomer and a photoinitiator containing a chain transfer group. The macrophotoinitiators are polymerized photochem. to give block copolymers. A photoinitiator prepared from I and methacrylic acid was polymerized with styrene using UV irradiation to give a block copolymer.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:392757 CAPLUS Full-text
DOCUMENT NUMBER: 129:68148
ORIGINAL REFERENCE NO.: 129:14150h,14151a
TITLE: α-aminoacetophenones as photoinitiators
INVENTOR(S): Ohwa, Masaki; Yamoto, Hitoshi; Birbaum, Jean-Luc; Nakashima, Hiroko; Matsumoto, Akira; Oka, Hidetaka
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 19753655 | A1 | 19980610 | DE 1997-19753655 | 19971203 <-- |
| DE 19753655 | B4 | 20080515 | | |
| IN 1997DE03201 | A | 20090313 | IN 1997-DE3201 | 19971107 |
| TW 452575 | B | 20010901 | TW 1997-86116781 | 19971108 <-- |
| GB 2320027 | A | 19980610 | GB 1997-23965 | 19971114 <-- |
| GB 2320027 | B | 20010509 | | |
| SG 73482 | A1 | 20000620 | SG 1997-4082 | 19971118 <-- |
| CH 692422 | A5 | 20020614 | CH 1997-2735 | 19971126 <-- |
| BE 1012647 | A5 | 20010206 | BE 1997-953 | 19971127 <-- |
| AU 9746773 | A | 19980611 | AU 1997-46773 | 19971128 <-- |
| AU 741581 | B2 | 20011206 | | |
| US 6022906 | A | 20000208 | US 1997-982147 | 19971201 <-- |

| | | | | | |
|---|---|---|---|---|---|
| CA 2223376 | A1 | 19980606 | CA 1997-2223376 | | 19971203 <-- |
| FR 2758139 | A1 | 19980710 | FR 1997-15289 | | 19971204 <-- |
| FR 2758139 | B1 | 20010420 | | | |
| NL 1007707 | A1 | 19980609 | NL 1997-1007707 | | 19971205 <-- |
| NL 1007707 | C2 | 19981027 | | | |
| CN 1184117 | A | 19980610 | CN 1997-125438 | | 19971205 <-- |
| CN 1134456 | C | 20040114 | | | |
| ZA 9710956 | A | 19980615 | ZA 1997-10956 | | 19971205 <-- |
| AT 500120 | A1 | 20051015 | AT 1997-2069 | | 19971205 |
| AT 500120 | B1 | 20070315 | | | |
| JP 10291969 | A | 19981104 | JP 1997-354199 | | 19971208 <-- |
| BR 9706068 | A | 20000321 | BR 1997-6068 | | 19981203 <-- |
| PRIORITY APPLN. INFO.: | | | EP 1996-810854 | A | 19961206 |
| | | | DE 1997-19753655 | T0 | 19971203 |

OTHER SOURCE(S): MARPAT 129:68148

AB The title compds., of specified structure. are prepared for use as initiators of photopolymn. Adding 120 mL PhCl dropwise to 0.41 mol 2-bromo-1-(4-fluorophenyl)2-methyl-1-propanone in 80 mL MeOH containing 0.45 mol NaOMe at 20° gave 90.8 g crude (4-fluorophenyl)-3,3-dimethyl-2-methoxyoxirane which, after vacuum distillation, was refluxed (0.35 mol) with 200 mL morpholine for 26 h to give 88.1 g 1-(4-fluorophenyl)-2-methyl-2-morpholinyl-1-propanone (I). Adding 80 mmol I in AcNMe2 over 14 h to 0.488 mol 1,3-propanedithiol and 22 g K2CO3 in AcNMe2 at 40° and stirring for 5 h gave 1-[4-[(3-mercaptopropyl)thio]phenyl]-2-methyl-2-morpholino-1-propanone. Use of the products in photopolymn. is exemplified.

L6 ANSWER 30 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:226847 CAPLUS Full-text

DOCUMENT NUMBER: 128:282789

ORIGINAL REFERENCE NO.: 128:55979a,55982a

TITLE: Preparation of N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

INVENTOR(S): Beard, Richard L.; Teng, Min; Colon, Diana F.; Duong, Tien T.; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan, USA

SOURCE: U.S., 21 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5739338 | A | 19980414 | US 1996-744210 | 19961105 <-- |
| CA 2270893 | A1 | 19980514 | CA 1997-2270893 | 19971029 <-- |
| CA 2270893 | C | 20081021 | | |
| WO 9819999 | A1 | 19980514 | WO 1997-US19915 | 19971029 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9851011 | A | 19980529 | AU 1998-51011 | 19971029 <-- |

| | | | | | | |
|---|---|---|---|---|---|---|
| AU 729997 | B2 | 20010222 | | | | |
| EP 937045 | A1 | 19990825 | EP 1997-913959 | | 19971029 | <-- |
| EP 937045 | B1 | 20040428 | | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | | | |
| JP 2001504458 | T | 20010403 | JP 1998-521637 | | 19971029 | <-- |
| AT 265436 | T | 20040515 | AT 1997-913959 | | 19971029 | |
| ES 2219760 | T3 | 20041201 | ES 1997-913959 | | 19971029 | |
| PRIORITY APPLN. INFO.: | | | US 1996-744210 | A | 19961105 | |
| | | | WO 1997-US19915 | W | 19971029 | |

OTHER SOURCE(S): MARPAT 128:282789

GI



I



II

AB The title compds. [I; R1 = H, C1-6 alkyl; R2 = C1-6 alkyl, F, Cl, Br, I; n = 0-3; R3 = C1-6 alkyl, F; X1, X2 = H, C1-6 alkyl; X1X2 = O; R4 = (un)substituted Ph, naphthyl, thienyl, etc.; Z = C.tplbond.C;(CR1:CR1)n (n = 0-5), CONR1; NR1CO; Y = (un)substituted Ph, naphthyl, heteroaryl; A = (CH2)q (q = 0-5), C3-6 alkyl, C3-6 cycloalkyl, etc.; B = H, COOH, CH2OH, etc.] having retinoid, retinoid antagonist or retinoid inverse agonist-like biol. activity, were prepared Thus, reaction of 4,4-dimethyl-1,2,3,4-tetrahydro-N-(4-methylphenyl)-7-ethynylquinoline (preparation described) with Et 4-iodobenzoate in the presence of Et3N, CuI and PdCl2(Ph3P)2 followed by hydrolysis of the resulting Et 4-{2-[4,4-dimethyl-1,2,3,4-tetrahydro-N-(4-methylphenyl)quinolin-7- yl]ethynyl}benzoate with aqueous LiOH in THF/MeOH afforded the title compound II which showed Ki of 13 nM against RARα binding.

REFERENCE COUNT: 117 THERE ARE 117 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:361630 CAPLUS Full-text

DOCUMENT NUMBER: 126:330623

ORIGINAL REFERENCE NO.: 126:64259a,64262a

TITLE: Preparation of 4-anilinopyrido[3,4-d]pyrimidines and analogs as protein tyrosine kinase inhibitors

INVENTOR(S): Cockerill, George Stuart; Guntrip, Stephen Barry; Mckeown, Stephen Carl; Page, Martin John; Smith, Kathryn Jane; Vile, Sadie; Hudson, Alan Thomas; Barraclough, Paul; Franzmann, Karl Witold; et al.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Cockerill, George Stuart; Guntrip, Stephen Barry; Mckeown, Stephen Carl; Page, Martin John; Smith, Kathryn Jane

SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9713771 | A1 | 19970417 | WO 1996-EP4399 | 19961010 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG | | | | |
| AU 9672896 | A | 19970430 | AU 1996-72896 | 19961010 <-- |
| ZA 9608551 | A | 19970718 | ZA 1996-8551 | 19961010 <-- |
| EP 861253 | A1 | 19980902 | EP 1996-934612 | 19961010 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 11513398 | T | 19991116 | JP 1996-514711 | 19961010 <-- |
| IN 1996DE02215 | A | 20050311 | IN 1996-DE2215 | 19961010 |
| US 6169091 | B1 | 20010102 | US 1998-51324 | 19980826 <-- |

PRIORITY APPLN. INFO.: GB 1995-20845 A 19951011
GB 1996-14757 A 19960713
WO 1996-EP4399 W 19961010

OTHER SOURCE(S): MARPAT 126:330623

GI




I




II

AB Title compds. [I; R = YZ1ZR4; R2 = H, halo, CF3, alkyl, alkoxy; R4 = cycloalkyl, Ph, thienyl, pyridyl, etc.; R6R7 = atoms to complete a (heteroaryl-substituted) heterocyclic ring; X = N or CH; Y = O, OCH2, SO0-2, (alkyl)imino, etc.; Z = O, CH2, NRb, OCH2, etc.; Rb = H or alkyl; NRbR4 = heterocyclyl; Z1 = (un)substituted phenylene] were prepared Thus, 4,6-dichloropyrido[3,4-d]pyrimidine was aminated by 4-(PhCH2O)C6H4NH2 and th product condensed with 5-tributylstannyl-N-methylimidazole to give title compound II. Data for biol. activity of I were given.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:205247 CAPLUS Full-text
DOCUMENT NUMBER: 126:205763
ORIGINAL REFERENCE NO.: 126:39656h,39657a,39658a
TITLE: Preparation of organosilicon compounds, and liquid-crystal composition and liquid-crystal display element
INVENTOR(S): Kondo, Tomoyuki; Matsui, Shuichi; Hachiya, Norihisa; Nakagawa, Etsuo
PATENT ASSIGNEE(S): Chisso Corp., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 9705144 | A1 | 19970213 | WO 1996-JP2103 | | 19960726 <-- |
| W: CN, JP, KR, US | | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | | |
| CN 1195352 | A | 19981007 | CN 1996-196782 | | 19960726 <-- |
| EP 872484 | A1 | 19981021 | EP 1996-925097 | | 19960726 <-- |
| EP 872484 | B1 | 20021002 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL | | | | | |
| AT 225353 | T | 20021015 | AT 1996-925097 | | 19960726 <-- |
| JP 3751640 | B2 | 20060301 | JP 1997-507462 | | 19960726 |
| US 5993690 | A | 19991130 | US 1998-409 | | 19980126 <-- |
| PRIORITY APPLN. INFO.: | | | JP 1995-211211 | A | 19950727 |
| | | | WO 1996-JP2103 | W | 19960726 |

OTHER SOURCE(S): MARPAT 126:205763
AB Organosilicon compds. represented by the general formula Ra-A-(Z1-A1)m-(Z2-A2)n-(Z3-A3)o-Rb [I; at least one of Ra, Rb, Z1, Z2 and Z3 has an SiH2 group; Ra = H or C1-2 alkyl wherein at least one CH2 group may be substituted by SiH2, O, S, CO, CH:CH, C.tplbond.C, or 1,4-cyclobutylene; Rb = a group of any of the Ra groups, halo or cyano; A, A1, A2 and A3 represent each a bivalent ring group; Z1, Z2 and Z3 represent each independently a covalent bond or (CH2)p wherein at least one CH2 group may be substituted by SiH2, O, S, CO, CH:CH or C.tplbond.C; p represents an integer of 1 to 4; m, n and o represent each independently 0 or 1], which are excellent in the compatibility with other liquid-crystal materials, reduced in viscosity, and improved in threshold voltage, are prepared A liquid crystal composition containing at least one silicon compound I and a liquid crystal display device using said liquid crystal composition are claimed. Thus, 10.0 g 4-bromo-4'-butoxybiphenyl was treated dropwise with BuLi in Et2O at -50°, stirred at -50° for 30 min, warmed to room temperature, stirred for 3 h, and resulting reaction mixture was added dropwise to a solution of 11.6 g propyltrichlorosilane in 10 mL THF at -50°, and stirred at -50° for 30 min and at room temperature for 48 h to give 4.6 g 4-propyldichlorosilyl-4'-butoxybiphenyl. The latter compound (3.0 g) was dissolved in Et2O and reduced by LiAlH4 at room temperature for 10 h to give 7.8% 4-propylsilyl-4'-butoxybiphenyl.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:186975 CAPLUS Full-text
DOCUMENT NUMBER: 126:212053

ORIGINAL REFERENCE NO.: 126:41007a,41010a
TITLE: Preparation of bis[bi(aryl/heteroaryl)] compounds as inhibitors of leukotriene biosynthesis
INVENTOR(S): Friesen, Richard; Dube, Daniel; Ducharme, Yves; Lepine, Carole; Delorme, Daniel; Hamel, Pierre
PATENT ASSIGNEE(S): Merck Frosst Canada Inc., Can.
SOURCE: Can. Pat. Appl., 80 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| CA 2169231 | A1 | 19960816 | CA 1996-2169231 | 19960209 <-- |
| US 5576338 | A | 19961119 | US 1995-388787 | 19950215 <-- |

PRIORITY APPLN. INFO.: US 1995-388787 A 19950215
OTHER SOURCE(S): MARPAT 126:212053
GI




II

AB The title compds. Ar1Ar2-X-Ar3Ar4 [I; Ar1, Ar4 = (un)substituted 5-membered aromatic ring containing one O or S and 0-3 N, 5-membered aromatic ring containing 1-4 N, 6-membered aromatic ring containing 0-3 N; Ar2 = (un)substituted arylene = 6-membered aromatic ring containing 0-3 N; Ar3 = (un)substituted arylene = 10-membered bicyclic aromatic ring containing 0-3 N, 2H-1-benzopyran-2-one, 2H-2-thioxo-1-benzopyran; X = OCH2, CH2O, O, S, S(O), S(O)2], useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents, and also in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques, were prepared Thus, reaction of 3-fluoro-5-(4-pyridyl)phenol with 7-bromomethyl-2-cyano-4-(3-furyl)quinoline in the presence of Cs2CO3 in DMF afforded the title compound II. In general, compds. I are effective at 0.1-10 mg/kg/day.

L6 ANSWER 34 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:134915 CAPLUS Full-text
DOCUMENT NUMBER: 126:144107
ORIGINAL REFERENCE NO.: 126:27853a,27856a
TITLE: Preparation of 5-aminoalkyl-2-(2-alkoxyphenyl)pyrroles having affinity for dopamine D3 receptors and their

use in the treatment of psychoses
INVENTOR(S): Watts, Eric Alfred
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Watts, Eric Alfred
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9700243 | A1 | 19970103 | WO 1996-EP2498 | 19960607 <-- |
| W: JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP 832064 | A1 | 19980401 | EP 1996-920811 | 19960607 <-- |
| R: BE, CH, DE, ES, FR, GB, IT, LI, NL | | | | |
| JP 11507657 | T | 19990706 | JP 1996-502608 | 19960607 <-- |

PRIORITY APPLN. INFO.: GB 1995-12129 A 19950615
WO 1996-EP2498 W 19960607
OTHER SOURCE(S): MARPAT 126:144107
GI



I

AB The title compds. [I; R1 = C1-4 alkyl; R3 = (un)substituted Ph, 5- or 6-membered heterocyclic aromatic group; R2, R4, R5 = H, halo, C1-4 alkyl, etc.; Y = 1-(1-piperidinyl)ethyl, N-substituted 2-pyrrolidinyl, 2-piperidinyl, etc.], dopamine D3 antagonists with potential for the treatment of schizophrenia, were prepared and formulated. Thus, treatment of N-acetylpiperidine with POCl3 followed by addition of 2-[(5-ethylsulfonyl-2-methoxy-4-phenyl)phenyl]-1H-pyrrole in ClCH2CH2Cl, and treatment of the reaction mixture with NaBH4 afforded 38% I [R1 = Me; R2, R5 = H; R3 = Ph; R4 = EtSO2; Y = 1-(1-piperidinyl)ethyl] which showed IC50 of 4 nM at the human D3 receptor.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 35 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:724140 CAPLUS Full-text
DOCUMENT NUMBER: 125:343103
ORIGINAL REFERENCE NO.: 125:63853a,63856a
TITLE: Optically active liquid crystal compound containing deuterium atoms for display device
INVENTOR(S): Koizumi, Yasuyuki; Demus, Dietrich; Matsui, Shuichi; Miyazawa, Kazutoshi; Sekiguchi, Yasuko; Nakagawa, Etsuo
PATENT ASSIGNEE(S): Chisso Corp., Japan
SOURCE: Eur. Pat. Appl., 88 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 735015 | A2 | 19961002 | EP 1996-300655 | 19960130 <-- |
| EP 735015 | A3 | 19970611 | | |
| R: CH, DE, FR, GB, IT, LI | | | | |
| JP 08325174 | A | 19961210 | JP 1995-347773 | 19951214 <-- |

PRIORITY APPLN. INFO.: JP 1995-100105 A 19950331
OTHER SOURCE(S): MARPAT 125:343103
GI



I

AB The title compound is represented by the formula I (R1, R2 = H, cyano, halogen, or alkyl or halogenated alkyl with 1-20 C atoms with the proviso that ≥1 methylene group in the alkyl group may be substituted by O, S, CH=CH, C.tplbond.C, CO, CF=CF, CF2, or a cycloalkane or cycloalkene ring with 3-5 C atoms; Z1-3 = a covalent bond or an alkylene group with 1-4 C atoms with the proviso that ≥1 methylene group in the alkylene group may be substituted by O, S, CH=CH, C.tplbond.C, CO, CF=CF, CF2, or a cycloalkane or cycloalkene ring with 3-5 C atoms; m, n = 0 or 1; rings A, B, C, D = a benzene, bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, naphthalene, 1,2,3,4-tetrahydronaphthalene, perhydronaphthalene, fluorene, phenanthrene, 9,10-dihydrophenanthrene, indane, indene, cycloalkane, or cycloalkene ring which may be substituted by O, S, or N atoms) with optically active C atoms bonded to D atoms. With the use of the title compound, it is possible to prepare a liquid crystal composition with controlled pitch and spiral direction without the use of a chiral dopant.

L6 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:616620 CAPLUS Full-text
DOCUMENT NUMBER: 125:275529
ORIGINAL REFERENCE NO.: 125:51521a,51524a
TITLE: Process for the stereospecific synthesis of azetidinones
INVENTOR(S): Thiruvengadam, Tiruvettipuram K.; Tann, Chou Hong; Mcallister, Timothy L.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 16 pp., Cont.-in-part of U. S. Ser. No. 179,008.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| US 5561227 | A | 19961001 | US 1994-265466 | 19940623 <-- |
| CA 2114007 | A1 | 19930204 | CA 1992-2114007 | 19920721 <-- |
| CA 2114007 | C | 20051220 | | |
| AU 9223980 | A | 19930223 | AU 1992-23980 | 19920721 <-- |
| AU 658441 | B2 | 19950413 | | |
| ZA 9205487 | A | 19930331 | ZA 1992-5487 | 19920721 <-- |
| EP 596015 | A1 | 19940511 | EP 1992-916790 | 19920721 <-- |
| EP 596015 | B1 | 19971001 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE | | | | |
| JP 06508637 | T | 19940929 | JP 1992-502964 | 19920721 <-- |
| JP 2525125 | B2 | 19960814 | | |
| US 5306817 | A | 19940426 | US 1992-962768 | 19921019 <-- |
| LV 10429 | B | 19950820 | LV 1992-550 | 19921229 <-- |
| LT 3369 | B | 19950825 | LT 1992-261 | 19921229 <-- |
| US 6093812 | A | 20000725 | US 1994-179008 | 19940107 <-- |
| NO 9400221 | A | 19940121 | NO 1994-221 | 19940121 <-- |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1991-734426 | B2 | 19910723 |
| US 1991-734652 | B2 | 19910723 |
| US 1992-962768 | A3 | 19921019 |
| US 1994-179008 | A2 | 19940107 |
| WO 1992-US5972 | W | 19920721 |

OTHER SOURCE(S): CASREACT 125:275529; MARPAT 125:275529

GI




I

AB Azetidinone derivs. are prepared stereospecifically by using a chiral oxazolidinone auxiliary. Thus, (R)-(+)-4-benzyl-2-oxazolidinone was acylated with Ph(CH2)4COCl, followed by aldol condensation with 4-MeOC6H4CHO, transamidation with 4-MeOC6H4NH2, and cyclization with EtO2CN:NCO2Et-PBu3 to give the azetidinone I.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:881320 CAPLUS Full-text

DOCUMENT NUMBER: 123:285781

ORIGINAL REFERENCE NO.: 123:51211a,51214a

TITLE: Preparation of (pyranylbenzyloxy)coumarins and analogs as leukotriene biosynthesis inhibitors

INVENTOR(S): Fortin, Rejean; Girard, Yves; Grimm, Erich; Hutchinson, John; Scheigetz, John

PATENT ASSIGNEE(S): Merck Frosst Canada Inc., Can.

SOURCE: Can. Pat. Appl., 85 pp.
CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| CA 2125824 | A1 | 19941224 | CA 1994-2125824 | | 19940614 | <-- |
| CA 2125824 | C | 20060711 | | | | |
| US 5424320 | A | 19950613 | US 1993-81528 | | 19930623 | <-- |
| PRIORITY APPLN. INFO.: | | | US 1993-81528 | A | 19930623 | |

OTHER SOURCE(S): CASREACT 123:285781; MARPAT 123:285781
GI




I

Q=







II

AB Title compds. [I; R = heterocyclyl group Q; R1 = H, OH, alkyl(oxy); R2,R4 = H, alkyl; R1R2 = O; R3 = H, (hydroxy)alkyl, alkoxyalkyl; R1R3 = (saturated)(oxa)alkylene; R7 = H, OH, alkyl(oxy), etc.; R9 = H, halo, OH, alkyl(oxy), etc.; R10 = H, alkyl, heteroaryl, etc.; R11,R12 = H, alkyl; R11R12 = bond; X1 = O, SO0-2, CH2; X2 = O, S, CH2, etc.; X3 = O, SO0-2, OCH2, CH2O, etc.; Z = (hetero)arylene; Z1 = CH(R5)m; R5 = H, OH, alkyl(oxy); m = 0 or 1] were prepared as leukotriene biosynthesis inhibitors (no data). Thus, 2,4-(HO)2C6H3COPh was etherified by 3-(4-hydroxytetrahydropyran-4-yl)benzyl bromide (preparation given) and the product cyclocondensed with Ph3P:CH2CO2Me to give title compound II.

L6 ANSWER 38 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:14536 CAPLUS Full-text
DOCUMENT NUMBER: 122:72018
ORIGINAL REFERENCE NO.: 122:13491a,13494a
TITLE: Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
INVENTOR(S): Girard, Yves; Delorme, Daniel; Fortin, Rejean; Dube, Daniel; Hamel, Pierre; Lepine, Carol; Ducharme, Yves
PATENT ASSIGNEE(S): Merck Frosst Canada, Inc., Can.
SOURCE: U.S., 39 pp. Cont.-in-part of U.S. Ser. No. 906,067, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5308852 | A | 19940503 | US 1992-936807 | 19920827 <-- |
| CA 2099061 | A1 | 19931230 | CA 1993-2099061 | 19930623 <-- |
| CA 2099061 | C | 20030819 | | |
| EP 579304 | A1 | 19940119 | EP 1993-201829 | 19930624 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| ZA 9304623 | A | 19931222 | ZA 1993-4623 | 19930628 <-- |
| AU 9341569 | A | 19940106 | AU 1993-41569 | 19930628 <-- |
| WO 9400444 | A1 | 19940106 | WO 1993-CA271 | 19930628 <-- |
| W: BB, BG, BR, BY, CZ, FI, HU, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US | | | | |
| RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CN 1087907 | A | 19940615 | CN 1993-109518 | 19930628 <-- |
| JP 06087847 | A | 19940329 | JP 1993-185527 | 19930629 <-- |
| JP 07116173 | B | 19951213 | | |

PRIORITY APPLN. INFO.: US 1992-906067 B2 19920629
US 1992-936807 A 19920827

OTHER SOURCE(S): MARPAT 122:72018
GI



I

AB Compds. I [R1, R5 = H, OH, lower alkyl, lower alkoxy; R2 = H, lower alkyl, or together with R1 forms :O; R3 = H, lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, or R1 and R3 may join to form mono-oxa, monocarbon bridge; R4, R6, R13 = H, lower alkyl; R7 = H, OH, lower alkyl, lower alkoxy, etc.; R8 = H, halo, lower alkyl, OH, lower alkoxy, CF3, CN, COR13; R9 = H, lower alkyl, lower alkoxy, hydroxy lower alkyl, etc.; R10, R11 = H, lower alkyl, lower alkoxy, hydroxy lower alkyl, lower alkoxy, etc.; X1, X2 = O, C(R6)2 (one but not both of X1 or X2 is O); X3 = C(R6)2O, OC(R6)2; Ar1 = arylene-(R8)2 (arylene = phenylene, pyridylene, thiaylene); Ar2 = aryl-(R9)2 (aryl = 5-membered aromatic ring with 1 O or S and 0-3 N, 5-membered aromatic ring with 1-4 N, 6-membered aromatic ring with 0-3 N, 2- or 4-pyranone, etc., with provisos)] are inhibitors of leukotriene biosynthesis. These compds. are useful as antiasthmatic, antiallergic, antiinflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection, and in preventing the formation of atherosclerotic plaques. Preparation of a large number of I and of intermediates therefor is included.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:298482 CAPLUS Full-text

DOCUMENT NUMBER: 120:298482
ORIGINAL REFERENCE NO.: 120:52604h,52605a
TITLE: Carbostyril derivatives and salts thereof, anti-arrhythmic agents containing them, and their preparation
INVENTOR(S): Tabusa, Fujio; Nagami, Kazuyoshi; Tsutsui, Hironori
PATENT ASSIGNEE(S): Higuchi, Yoshinari, Japan
SOURCE: Pat. Specif. (Aust.), 148 pp.
CODEN: ALXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| AU 639529 | B2 | 19930729 | AU 1991-70939 | 19910211 <-- |
| AU 9170939 | A | 19910509 | | |

PRIORITY APPLN. INFO.: AU 1991-70939 19910211
OTHER SOURCE(S): MARPAT 120:298482
GI



I

AB Carbostyrils and dihydro derivs. I [R1 = H, alkyl, alkenyl, alkynyl, phenylalkyl, carboxyalkyl, phenylalkoxyalkyl, amidoalkyl, saturated heterocyclylcarbonylalkyl; R2 = N3, azidocarbonyl, phthalimido, pyrrolidinyl, pyridyl, various (un)substituted NH2 groups, piperidinyl, quinuclidinyl; R3 = alkyl, haloalkyl, alkoxy, OH, halo, CO2H, Ph, phenylalkoxy, alkenyloxy, alkanoylalkoxy, alkylaminocarbonylalkoxy; n = 0, 1, 2; optional 3,4-double bond], some of which are novel and/or prepared, are useful as antiarrhythmics. For example, cyclization of 2-[2-(4-benzyl-1-piperidinyl)acetyl]amino-3-methylbenzaldehyde by NaOEt in refluxing EtOH gave I [R1 = H, R2 = 8-Me, R3 = 3-(4-benzyl-1-piperidinyl); Δ3 present], isolated as the HCl salt. Various I were active at 3-300 μmol doses when tested against elec.-stimulated contractions of isolated feline cardiac muscle samples. Approx. 170 I (free bases and/or salts) are listed with phys. data, and antiarrhythmic test data are given for 27 compds.

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 08:17:15 ON 06 APR 2009